Skip to main content

Advertisement

Table 1 Demographic characteristicsa, b

From: A cluster randomized trial to assess the effect of clinical pathways for patients with stroke: results of the clinical pathways for effective and appropriate care study

Characteristics Clinical pathway, n = 238 No intervention, n = 238 Between-group difference, OR (95% CI) P-valueb
Age, years (mean ± SD) 74.5 ± 10.8 74.0 ± 11.7 - 0.61
Male gender 138/238 (58.0) (51.4 to 64.3) 98/238 (41.2) (34.9 to 47.7) 1.97 (1.35 to 2.89) < 0.001
Previous stroke 50/215 (23.3) (17.8 to 29.5) 57/207 (27.5) (21.6 to 34.2) 0.80 (0.50 to 1.27) 0.32
Current smoking status 29/229 (12.7) (12.4 to 22.5) 25/219 (11.4) (3.9 to 11.0) 1.13 (0.61 to 2.07) 0.77
Hypertension 132/229 (57.6) (51.0 to 64.1) 103/219 (47.0) (40.3 to 53.9) 1.53 (1.04 to 2.27) 0.03
Heart failure 86/229 (37.5) (30.0 to 42.8) 78/219 (35.6) (30.6 to 43.8) 1.09 (0.73 to 1.63) 0.69
Coronary heart disease 21/229 (9.2) (5.8 to 13.7) 29/219 (13.2) (9.1 to 18.5) 0.66 (0.35 to 1.25) 0.18
Peripheral vasculopathy 73/229 (31.9) (25.9 to 38.3) 46/219 (21.0) (15.8 to 27.0) 1.76 (1.12 to 2.76) < 0.01
Diabetes mellitus 52/229 (22.7) (17.4 to 28.7) 73/219 (31.5) (27.1 to 40.0) 0.59 (0.38 to 0.91) 0.01
Diabetes mellitus (organ pathology) 7/229 (3.1) (1.2 to 6.2) 9/219 (4.1) (1.9 to 7.8) 0.74 (0.24 to 2.20) 0.62
COPD 24/229 (10.5) (6.8 to 15.2) 51/219 (23.3) (17.9 to 29.5) 0.48 (0.28 to 0.83) < 0.01
Cerebrovascular pathology 60/229 (26.2) (20.6 to 32.4) 82/219 (37.4) (31.0 to 44.2) 0.59 (0.39 to 0.90) 0.01
Pressure ulcer 4/229 (1.8) (0.5 to 4.4) 11/219 (5.0) (2.5 to 8.8) 0.35 (0.09 to 1.22) 0.06
Hemiplegy 16/229 (7.0) (4.0 to 11.1) 22/219 (10.1) (6.4 to 14.8) 0.67 (0.33 to 1.38) 0.31
Nephropathy 10/229 (4.4) (2.1 to 7.9) 13/219 (5.9) (3.2 to 9.9) 0.72 (0.29 to 1.81) 0.52
Dementia 24/229 (10.5) (6.8 to 15.2) 10/219 (6.0) (2.2 to 8.2) 2.45 (1.08 to 5.63) 0.02
Hepatopathy 7/229 (3.1) (1.2 to 6.2) 6/219 (2.7) (1.0 to 5.9) 1.12 (0.33 to 1.82) 1
   Cancer     
Solid metastasis 2/229 (0.9) (0.1 to 3.1) 3/219 (1.4) (0.3 to 4.0) 0.63 (0.07 to 4.70) 0.68
Leukemia 2/229 (0.9) (0.1 to 3.1) 3/219 (1.4) (0.3 to 4.0) 0.63 (0.07 to 4.70) 0.68
Lymphoma 1/229 (0.4) (0.0 to 2.4) 0/219 (0.0) (0.0 to 1.7) 1.08 (0.14 to 1.92) 1
Others 11/229 (4.8) (2.4 to 8.4) 19/219 (8.7) (3.8 to 14.7) 0.53 (0.23 to 1.21) 0.10
  1. aBecause of missing data denominators used to calculate percentages may differ from group totals (clinical pathway versus no intervention).
  2. bValues are n/total n (%) (95% CI) unless otherwise indicated.
  3. c P-values represent comparison of each characteristic between two groups (clinical pathway versus no intervention), and all P-values are two-sided.